Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549451639> ?p ?o ?g. }
- W2549451639 endingPage "209" @default.
- W2549451639 startingPage "200" @default.
- W2549451639 abstract "Background Little is known about the effects of phosphorus additives on patients with kidney disease. Study Design Randomized, double-blind, crossover trial. Setting & Participants 31 adults with early stages of presumed chronic kidney disease (estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2; urine albumin-creatinine ratio sex-specific cutoff points: men ≥ 17 mg/g, women ≥ 25 mg/g). Intervention Higher versus lower phosphorus intake for 3 weeks. Higher phosphorus intake was achieved by the addition of commercially available diet beverages and breakfast bars to diet. Outcomes Change in 24-hour urine albumin excretion and plasma fibroblast growth factor 23 level. Measurements Two 24-hour urine collections and a single fasting blood draw at the end of each period. Results Mean baseline values for phosphorus intake, 24-hour urine phosphorus excretion, and estimated glomerular filtration rate were 1,113 ± 549 (SD) mg/d, 688 ± 300 mg/d, and 74.6 ± 22.0 mL/min/1.73 m2. Median urine albumin excretion of 82.7 (IQR, 39.6-174.1) mg/d. Although phosphorus intake from study products increased by 993 mg/d (P < 0.001) during the higher compared to lower phosphorus additive period, background phosphorus intake decreased by 151 mg/d (P = 0.004). Higher phosphorus additive consumption increased 24-hour urine phosphorus excretion by 505 (95% CI, 381 to 629) mg/d (P < 0.001), but did not significantly increase albuminuria (higher vs lower: 14.3%; 95% CI, −2.5% to 34.0%; P = 0.1) or fibroblast growth factor 23 level (higher vs lower: 3.4%; 95% CI, −5.9% to 13.6%; P = 0.4). Limitations Small sample size, short duration of intervention, changes in background diet during the intervention. Conclusions A 3-week consumption of higher phosphorus food additives did not significantly increase albuminuria. Further studies are needed to confirm these results. Little is known about the effects of phosphorus additives on patients with kidney disease. Randomized, double-blind, crossover trial. 31 adults with early stages of presumed chronic kidney disease (estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2; urine albumin-creatinine ratio sex-specific cutoff points: men ≥ 17 mg/g, women ≥ 25 mg/g). Higher versus lower phosphorus intake for 3 weeks. Higher phosphorus intake was achieved by the addition of commercially available diet beverages and breakfast bars to diet. Change in 24-hour urine albumin excretion and plasma fibroblast growth factor 23 level. Two 24-hour urine collections and a single fasting blood draw at the end of each period. Mean baseline values for phosphorus intake, 24-hour urine phosphorus excretion, and estimated glomerular filtration rate were 1,113 ± 549 (SD) mg/d, 688 ± 300 mg/d, and 74.6 ± 22.0 mL/min/1.73 m2. Median urine albumin excretion of 82.7 (IQR, 39.6-174.1) mg/d. Although phosphorus intake from study products increased by 993 mg/d (P < 0.001) during the higher compared to lower phosphorus additive period, background phosphorus intake decreased by 151 mg/d (P = 0.004). Higher phosphorus additive consumption increased 24-hour urine phosphorus excretion by 505 (95% CI, 381 to 629) mg/d (P < 0.001), but did not significantly increase albuminuria (higher vs lower: 14.3%; 95% CI, −2.5% to 34.0%; P = 0.1) or fibroblast growth factor 23 level (higher vs lower: 3.4%; 95% CI, −5.9% to 13.6%; P = 0.4). Small sample size, short duration of intervention, changes in background diet during the intervention. A 3-week consumption of higher phosphorus food additives did not significantly increase albuminuria. Further studies are needed to confirm these results." @default.
- W2549451639 created "2016-11-30" @default.
- W2549451639 creator A5011594229 @default.
- W2549451639 creator A5016958559 @default.
- W2549451639 creator A5031574122 @default.
- W2549451639 creator A5039267010 @default.
- W2549451639 creator A5045050293 @default.
- W2549451639 creator A5048680434 @default.
- W2549451639 creator A5053852808 @default.
- W2549451639 creator A5056717320 @default.
- W2549451639 creator A5062344279 @default.
- W2549451639 creator A5064188100 @default.
- W2549451639 creator A5075819696 @default.
- W2549451639 date "2017-02-01" @default.
- W2549451639 modified "2023-10-03" @default.
- W2549451639 title "Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial" @default.
- W2549451639 cites W1485611107 @default.
- W2549451639 cites W1803609188 @default.
- W2549451639 cites W1864608164 @default.
- W2549451639 cites W1968286086 @default.
- W2549451639 cites W1973638806 @default.
- W2549451639 cites W1973663762 @default.
- W2549451639 cites W1976014411 @default.
- W2549451639 cites W1983292120 @default.
- W2549451639 cites W1997311322 @default.
- W2549451639 cites W2005969628 @default.
- W2549451639 cites W2007271927 @default.
- W2549451639 cites W2007937881 @default.
- W2549451639 cites W2011871493 @default.
- W2549451639 cites W2015668150 @default.
- W2549451639 cites W2022644695 @default.
- W2549451639 cites W2028478064 @default.
- W2549451639 cites W2033826233 @default.
- W2549451639 cites W2037498463 @default.
- W2549451639 cites W2038982333 @default.
- W2549451639 cites W2042722289 @default.
- W2549451639 cites W2053516867 @default.
- W2549451639 cites W2059022155 @default.
- W2549451639 cites W206350766 @default.
- W2549451639 cites W2066150501 @default.
- W2549451639 cites W2075296396 @default.
- W2549451639 cites W2076235974 @default.
- W2549451639 cites W2080073410 @default.
- W2549451639 cites W2089974569 @default.
- W2549451639 cites W2094551185 @default.
- W2549451639 cites W2100142196 @default.
- W2549451639 cites W2101164884 @default.
- W2549451639 cites W2102734552 @default.
- W2549451639 cites W2105398326 @default.
- W2549451639 cites W2106911759 @default.
- W2549451639 cites W2110435733 @default.
- W2549451639 cites W2115391512 @default.
- W2549451639 cites W2137069121 @default.
- W2549451639 cites W2140249287 @default.
- W2549451639 cites W2144043457 @default.
- W2549451639 cites W2145982046 @default.
- W2549451639 cites W2152576509 @default.
- W2549451639 cites W2153481494 @default.
- W2549451639 cites W2155965977 @default.
- W2549451639 cites W2164074621 @default.
- W2549451639 cites W2167551217 @default.
- W2549451639 cites W2176139377 @default.
- W2549451639 cites W2321986725 @default.
- W2549451639 cites W2475261460 @default.
- W2549451639 cites W2607031541 @default.
- W2549451639 doi "https://doi.org/10.1053/j.ajkd.2016.08.029" @default.
- W2549451639 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5263092" @default.
- W2549451639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27865566" @default.
- W2549451639 hasPublicationYear "2017" @default.
- W2549451639 type Work @default.
- W2549451639 sameAs 2549451639 @default.
- W2549451639 citedByCount "22" @default.
- W2549451639 countsByYear W25494516392016 @default.
- W2549451639 countsByYear W25494516392017 @default.
- W2549451639 countsByYear W25494516392018 @default.
- W2549451639 countsByYear W25494516392019 @default.
- W2549451639 countsByYear W25494516392020 @default.
- W2549451639 countsByYear W25494516392021 @default.
- W2549451639 countsByYear W25494516392022 @default.
- W2549451639 countsByYear W25494516392023 @default.
- W2549451639 crossrefType "journal-article" @default.
- W2549451639 hasAuthorship W2549451639A5011594229 @default.
- W2549451639 hasAuthorship W2549451639A5016958559 @default.
- W2549451639 hasAuthorship W2549451639A5031574122 @default.
- W2549451639 hasAuthorship W2549451639A5039267010 @default.
- W2549451639 hasAuthorship W2549451639A5045050293 @default.
- W2549451639 hasAuthorship W2549451639A5048680434 @default.
- W2549451639 hasAuthorship W2549451639A5053852808 @default.
- W2549451639 hasAuthorship W2549451639A5056717320 @default.
- W2549451639 hasAuthorship W2549451639A5062344279 @default.
- W2549451639 hasAuthorship W2549451639A5064188100 @default.
- W2549451639 hasAuthorship W2549451639A5075819696 @default.
- W2549451639 hasBestOaLocation W25494516392 @default.
- W2549451639 hasConcept C10146269 @default.
- W2549451639 hasConcept C126322002 @default.
- W2549451639 hasConcept C134018914 @default.
- W2549451639 hasConcept C142724271 @default.
- W2549451639 hasConcept C159641895 @default.